Fungal Infection is a major cause of morbidity worldwide. Fungal Infections are caused by different fungi found in environment. Although, some fungi are not dangerous at all but few types of fungi are harmful to health. It involves the invasion of tissue such as skin and lung by specific type of fungi. According to Centers for Disease Control and Prevention (CDC), a public health institute in the U.S., approximately 1.5 million different species of fungi are present on earth. Out of them, 300 fungi species cause fungal infection in humans. Fungal Infection Trust, a U.K. based organization for the improvement of quality of life of fungal infected patient observed that approximately billion people are affected by fungal infection every year. It is most common among people who are using antineoplastic agents, immunosuppressive agents, broad-spectrum antibiotics and prosthetic devices. Patients with HIV infection, burns, neutropenia and pancreatitis are at high risk of developing fungal infection.
The fungal infection pipeline has more than 60 drugs. In pipeline analysis, drugs are analyzed based on route of administration and molecule type. The pipeline is also analyzed on the basis of monotherapy and combination therapy, and different clinical phases including Phase III, Phase II, Phase I and Pre-clinical stage.
VB 2862 is a pre-clinical drug candidate of Vyom Biosciences for the treatment of recalcitrant tinea infections. The company is using molecular replacement therapy platform for the development of VB 2862. Preclinical study is also known as animal study. It is done before testing a drug in people to find out the toxicity profile of the drug. Preclinical study is of two types, including in vitro and in vivo.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/fungal-infections-pipeline-analysis/toc-sample
Pipeline analysis provides description about the key companies developing fungal infections drugs. Some of the key players actively involved in the research and development are Moberg Pharma AB, Viamet Pharmaceuticals, Inc., Pulmocide Ltd., Vyom Biosciences, NovaDigm Therapeutics Inc., Matinas BioPharma Holdings Inc., Sol-Gel Technologies Ltd. and Eisai Co. Ltd.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)